Key facts
- It has raised $4.1M; the latest was Accelerator/Incubator in Jan 2025.
- Notable investors include Investissement Quebec, Québec Tech, AQC Capital, Anges Québec, Frederic Ors — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Saguaro (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Saguaro (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Saguaro (Drug Discovery)
Developer of cell culture technologies designed to accelerate development and discoveries in life sciences. The company's products help drug developers generate new data that is more predictive of results in clinical trials with humans, enabling scientists to make the most of their lab-grown disease models.
- Sector
- Healthcare
- HQ
- Quebec, Canada
- Founded
- 2020
- Employees
- 7
- Website
- saguarobio.com/
- Ownership
- Privately Held (backing)
Saguaro (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Saguaro (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Saguaro (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.